Federal medicines regulators face mounting pressure to restrict the prescribing of unapproved peptide substances following the sudden death of veteran Australian film stuntman and martial artist Richard Norton.
Norton, 75, suffered a fatal cardiac arrest in March 2025 shortly after injecting a combination of CJC-1295 and ipamorelin, compounds frequently marketed within anti-ageing, body-building, and alternative wellness circles, The Guardian Australia reported. While the substances had been prescribed by an Australian medical practitioner, neither carries approval from the Therapeutic Goods Administration (TGA) for general therapeutic use.
Fatal Dose of Unregulated Growth Compounds
Coronial findings into Norton's death have illuminated the burgeoning, loosely monitored trade in synthetic peptides across the country. Both CJC-1295 and ipamorelin are synthetic growth hormone secretagogues, chemical agents engineered to trigger the pituitary gland into releasing human growth hormone.
Proponents champion such compounds for tissue regeneration, muscular development, and cellular recovery. However, clinical researchers have long warned that their cardiovascular side-effects, long-term biological interactions, and chemical purity profiles remain inadequately tested in rigorous human trials.
According to reporting by The Guardian Australia, Norton collapsed almost immediately following the self-administration of the prescribed substances. Paramedics were dispatched to his residence, but extensive resuscitation efforts proved unsuccessful.
Regulatory Blind Spots in Off-Label Prescribing
Under existing Commonwealth pharmaceutical frameworks, registered medical practitioners are permitted to prescribe unapproved substances via specific exemptions, including compounded pharmaceuticals and special access pathways.
Critics within the medical fraternity have raised concerns that these exemptions are increasingly leveraged to supply under-researched wellness products directly to consumers. Such transactions often bypass the strict efficacy and toxicology benchmarks demanded of mainstream pharmaceuticals registered on the Australian Register of Therapeutic Goods.
The coroner examining Norton's death observed that current oversight arrangements fail to shield consumers adequately from severe physiological hazards, particularly older patients who may live with undiagnosed or subclinical cardiovascular vulnerabilities.
TGA Review Urged to Protect Consumers
Handing down findings, the coroner formally urged the TGA to reassess the domestic distribution, importation, and compounding of experimental peptide products. Potential interventions could include tighter restrictions on prescribing rights, enhanced clinical warnings, and outright prohibitions on compounds lacking robust safety documentation.
A federal review would follow broader scrutiny of unregulated performance products, with regulators previously moving against the illicit supply of unregistered hormonal therapies and synthetic weight-loss compounds.
Medical authorities remain concerned that aggressive commercial marketing often misleads the public into viewing potent endocrine-altering drugs as harmless nutritional supplements, masking the profound cardiovascular strain they can induce.
A Celebrated Legacy in Stunt Choreography
The coronial findings represent a sombre postscript to the life of one of Australia's premier action cinema veterans. Born in Croydon, Victoria, Norton forged a globally recognised career spanning more than five decades.
He worked extensively across Hollywood and Hong Kong, sharing screens and training floors with martial arts icons such as Jackie Chan, Chuck Norris, and Jean-Claude Van Damme. In later years, Norton served as an elite fight coordinator and stunt director on international blockbusters, including George Miller's acclaimed Mad Max: Fury Road.
Industry peers have expressed profound grief at his loss, as healthcare advocates press authorities to ensure coronial recommendations translate into swift legislative reform.
